Benitec Biopharma Inc. (BNTC) · Full Year 2026
BNTC — FY2026 Annual Report Analysis
Benitec ended FY2026 (June year-end) with no revenue and a $45.5M net loss, but 58% of that loss was non-cash stock compensation — actual cash burn fell 30% to $16.5M against a $180.0M cash balance, leaving a clinical-stage biotech with roughly a decade of runway and one asset, BB-301, to prove.